Literature DB >> 20831860

Quantitative analysis of influenza M2 channel blockers.

Peleg Astrahan1, Ravenna Flitman-Tene, Estelle R Bennett, Miriam Krugliak, Chaim Gilon, Isaiah T Arkin.   

Abstract

The influenza M2 H(+) channel enables the concomitant acidification of the viral lumen upon endosomic internalization. This process is critical to the viral infectivity cycle, demonstrated by the fact that M2 is one of only two targets for anti-flu agents. However, aminoadamantyls that block the M2 channel are of limited therapeutic use due to the emergence of resistance mutations in the protein. Herein, using an assay that involves expression of the protein in Escherichia coli with resultant growth retardation, we present quantitative measurements of channel blocker interactions. Comparison of detailed K(s) measurements of different drugs for several influenza channels, shows that the swine flu M2 exhibits the highest resistance to aminoadamantyls of any channel known to date. From the perspective of the blocker, we show that rimantadine is consistently a better blocker of M2 than amantadine. Taken together, such detailed and quantitative analyses provide insight into the mechanism of this important and pharmaceutically relevant channel blocker system.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20831860     DOI: 10.1016/j.bbamem.2010.08.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Structural basis for the function and inhibition of an influenza virus proton channel.

Authors:  Amanda L Stouffer; Rudresh Acharya; David Salom; Anna S Levine; Luigi Di Costanzo; Cinque S Soto; Valentina Tereshko; Vikas Nanda; Steven Stayrook; William F DeGrado
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

2.  Bacteria-based analysis of HIV-1 Vpu channel activity.

Authors:  Robert Taube; Raphael Alhadeff; Dror Assa; Miriam Krugliak; Isaiah T Arkin
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

3.  SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine.

Authors:  Prabhat Pratap Singh Tomar; Isaiah T Arkin
Journal:  Biochem Biophys Res Commun       Date:  2020-06-20       Impact factor: 3.575

4.  Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus.

Authors:  Maggie C Duncan; Pascal Amoa Onguéné; Ibuki Kihara; Derrick N Nebangwa; Maya E Naidu; David E Williams; Aruna D Balgi; Kerstin Andrae-Marobela; Michel Roberge; Raymond J Andersen; Masahiro Niikura; Fidele Ntie-Kang; Ian Tietjen
Journal:  Molecules       Date:  2020-06-24       Impact factor: 4.411

5.  Potential Viroporin Candidates From Pathogenic Viruses Using Bacteria-Based Bioassays.

Authors:  Prabhat Pratap Singh Tomar; Rivka Oren; Miriam Krugliak; Isaiah T Arkin
Journal:  Viruses       Date:  2019-07-09       Impact factor: 5.048

6.  Searching for Blockers of Dengue and West Nile Virus Viroporins.

Authors:  Hiya Lahiri; Isaiah T Arkin
Journal:  Viruses       Date:  2022-08-11       Impact factor: 5.818

7.  Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay.

Authors:  Aruna D Balgi; Jun Wang; Daphne Y H Cheng; Chunlong Ma; Tom A Pfeifer; Yoko Shimizu; Hilary J Anderson; Lawrence H Pinto; Robert A Lamb; William F DeGrado; Michel Roberge
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

8.  An assay suitable for high throughput screening of anti-influenza drugs.

Authors:  Lili Mao; Jun Wang; William F DeGrado; Masayori Inouye
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

9.  Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.

Authors:  Prabhat Pratap Singh Tomar; Miriam Krugliak; Isaiah T Arkin
Journal:  Viruses       Date:  2021-03-23       Impact factor: 5.048

10.  Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library.

Authors:  Prabhat Pratap Singh Tomar; Miriam Krugliak; Isaiah T Arkin
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.